Condition 1: Polycystic Ovary Syndrome. Condition 2: Primary dysmenorrhea. Polycystic ovarian syndrome Primary dysmenorrhea
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Each patient consumes anise powder (5 grams) from the first day of menstruation to the third day of menstruation twice a day (with lunch and din
Sponsors
Sabzevar University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: People with primary dysmenorrhea with a score higher than 5 according to the visual pain scale Informed consent to participate in the research Age between 15-45 years old Having regular periods with intervals of 21-35 days according to the statements of the research units Not having a history of physical diseases such as asthma, allergies, migraines, diabetes, thalassemia, blood pressure, thyroid, and cardiovascular diseases according to the research units Not having pelvic inflammatory diseases, diagnosed uterine problems, such as abnormal bleeding and ovarian cysts, according to the research units Not taking hormonal drugs and oral contraceptive pills during the last 3 months according to the statement of the research units The absence of accidents during the last 6 months according to the statements of the research units Lack of sensitivity to medicinal and chemical plants according to the statements of the research units The onset of menstrual pain at the same time as the onset of menstrual bleeding or a few hours before the onset of menstruation and lasting for a maximum of 48-72 hours
Exclusion criteria
Exclusion criteria: Unwillingness to continue participating in the study The occurrence of abnormal bleeding during the study The use of painkillers except Mefenamic acid during the research period The occurrence of any signs of allergic reaction based on the observation of the researcher and the statements of the research units Failure to use the drug according to the recommended method History of endometriosis and severe digestive problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity. Timepoint: At the end of each day. Method of measurement: Visual Analogue Scale (VAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain duration. Timepoint: 3 months after taking the drug/placebo. Method of measurement: WaLIDD (working ability, location, intensity, days of pain, dysmenorrhea) score.;Analgesics usage. Timepoint: 3 months after taking the drug/placebo. Method of measurement: Questionnaire.;Muscle contusion. Timepoint: 3 months after taking the drug/placebo. Method of measurement: Moos Menstrual Distress Questionnaire.;Nausea and vomiting. Timepoint: 3 months after taking the drug/placebo. Method of measurement: Moos Menstrual Distress Questionnaire.;Mood swings. Timepoint: 3 months after taking the drug/placebo. Method of measurement: Moos Menstrual Distress Questionnaire.;Leg and foot edema. Timepoint: 3 months after taking the drug/placebo. Method of measurement: Moos Menstrual Distress Questionnaire.;Ability to perform daily tasks. Timepoint: 3 months after taking the drug/placebo. Method of measurement: WaLIDD (working ability, location, intensity, days of pain, dysmenorrhea) score.;Number of pain sites. Timepoint: 3 months after taking the drug/placebo. Method of measurement: WaLIDD (working ability, location, intensity, days of pain, dysmenorrhea) score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSahar Roshan
Sabzevar University of Medical Sciences
Outcome results
None listed